Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations

Dow Jones

01/09

By Elias Schisgall

Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.

Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.

Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.

Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 08, 2026 11:24 ET (16:24 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2602396401"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602396401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602396401?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602396401","market":"hk","top_or_hot":-1,"title":"Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-09 00:24</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602396401","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602396401","pubTimestamp":1767889440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AMRN":"阿玛琳"},"translate_title":"Amarin股价因现金流超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n\n\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n\n\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n\n\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 11:24 ET (16:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}